Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19

Status Recruiting

Clinical Trial Summary

Pulmonary fibrosis is a sequela of severe infection COVID-19.The prevalence of PCFP ranged from 2% to 45%,and the pathogenesis of PCFP has not been clearly elucidated.The ingredient of Bailing capsule is Cs-C-Q80,it has obvious protective effect on lung. Studies have shown that Bailing capsule may improve the clinical symptoms of PCPF patients through anti-fibrosis, oxidation and anti-inflammatory effects in multiple pathways. The purpose of this study was to evaluate the efficacy and safety of bailing capsule in treating PCFP after COVID-19 infection.

Clinical Trial Description

This is a multicenter, prospective, open, randomized controlled clinical study. Bailing capsule was used for 12 weeks of convalescent treatment in patients with COVID-19 infection to evaluate the efficacy and safety of Bailing capsule on pulmonary fibrosis changes after COVID-19 infection. The study consisted of a 1-week screening period and a 12-week randomized treatment period. Screening period (V0) : All subjects who have signed informed consent will enter a screening period (up to 7 days) to assess eligibility. Subjects with confirmed pulmonary fibrosis changes after COVID-19 infection were required to complete relevant procedures, examinations and assessments according to the study procedure table during the screening period. Randomized treatment period (V1~V3) : The randomized treatment period included V1 to V3 visits. At baseline visit (V1), eligible subjects will be randomly assigned to 6 capsules of Bailing Capsule, tid group, or blank control group in a 1:1 ratio, and receive appropriate treatment during the treatment period: 1. Experimental group: 6 capsules of Bailing capsule, tid group (n=121), a total of 12 weeks. 2. Control group: blank control (n=121). During randomized treatment, subjects will be required to complete procedures, examinations, and evaluations according to the study protocol. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05890573
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact	Haibin Dai, Professor
Phone	+860571-87783891
Email	haibindai@zju.edu.cn
Status	Recruiting
Phase	N/A
Start date	April 16, 2024
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04901676` - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	Phase 3
Not yet recruiting	`NCT04534478` - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19	Phase 4
Active, not recruiting	`NCT05002517` - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab	Phase 3
Completed	`NCT05008393` - Efficacy of PJS-539 for Adult Patients With COVID-19.	Phase 2
Completed	`NCT04569877` - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia	Phase 2
Not yet recruiting	`NCT05286255` - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias	Phase 1
Completed	`NCT05035589` - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting	`NCT06113432` - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study	N/A
Recruiting	`NCT05042063` - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting	`NCT04615429` - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19	Phase 2
Completed	`NCT05047653` - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting	`NCT05047016` - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY	N/A
Active, not recruiting	`NCT05033847` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 2
Recruiting	`NCT06113757` - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease	N/A
Completed	`NCT05504655` - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting	`NCT05035524` - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19	N/A
Completed	`NCT05065879` - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes	Phase 4
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Withdrawn	`NCT04460105` - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia	Phase 1
Suspended	`NCT04901689` - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	Phase 3